tiprankstipranks
Trending News
More News >
Sleep Number (SNBR)
NASDAQ:SNBR

Sleep Number (SNBR) AI Stock Analysis

Compare
446 Followers

Top Page

SNBR

Sleep Number

(NASDAQ:SNBR)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
$3.50
▲(5.74% Upside)
Action:ReiteratedDate:03/13/26
The score is held down primarily by very weak financial performance (losses, inconsistent/negative cash generation, and a stressed balance sheet with negative equity) and strong bearish technicals (price well below moving averages with negative momentum). A moderately constructive earnings-call outlook (cost cuts, EBITDA improvement, and a target for positive free cash flow) provides some offset, but valuation is not supportive given losses and no indicated yield.
Positive Factors
High product gross margins
Sleep Number’s product mix retains structurally high gross margins (~57%–60%), and ComfortMode shows an incremental ~10 percentage point margin benefit. Durable mattress-level margins give the company room to invest in marketing and absorb markdowns while still restoring operating profitability over several quarters.
Rapid product reset and simplified lineup
A faster-than-typical product reset and SKU simplification reduce complexity, inventory carrying risk, and go-to-market time. Those structural changes improve assortment clarity, lower SG&A and fulfillment costs per unit, and support steadier sales and margin recovery over a multi-quarter horizon.
Material fixed-cost reductions
Large executed cost actions ($185M) plus $50M more materially reduce the fixed-cost base, improving operating leverage. Permanently lower structural costs can turn modest revenue growth into outsized EBITDA gains and reduce cash burn, supporting a sustainable path to positive free cash flow.
Negative Factors
Stressed capital structure
Negative equity and very high debt relative to assets indicate a stressed capital structure that limits flexibility. Persistent negative equity raises refinancing and covenant risk, constraining investment, marketing cadence and the ability to withstand prolonged demand weakness without dilutive or costly capital fixes.
Inconsistent and negative cash generation
Reversion to negative operating and free cash flow in the trailing twelve months undermines the company’s ability to self-fund operations and service debt. Inconsistent cash generation raises reliance on external financing and makes multi-quarter turnaround execution and inventory resets more precarious.
Sustained top-line pressure
Material revenue declines and unit deleverage reduce the benefit of high gross margins and hamper operating leverage recovery. Persistent demand weakness forces markdowns, slows inventory turn, and lengthens the timeline to restore profitability and normalize cash flow even after cost cuts are realized.

Sleep Number (SNBR) vs. SPDR S&P 500 ETF (SPY)

Sleep Number Business Overview & Revenue Model

Company DescriptionSleep Number Corporation, together with its subsidiaries, offers sleep solutions and services in the United States. The company designs, manufactures, markets, retails, and services beds, pillows, sheets, and other bedding products under the Sleep Number name. It also provides adjustable bases under the FlextFit, and smart beds under the Sleep Number 360 brands. The company sells its products directly to consumers through retail, online, phone, and chat as well as through its e-commerce activities. As of January 2, 2022, it operated approximately 648 retail stores in 50 states. The company was formerly known as Select Comfort Corporation and changed its name to Sleep Number Corporation in November 2017. Sleep Number Corporation was founded in 1987 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneySleep Number primarily makes money by selling products directly to consumers (DTC). Its core revenue stream is the sale of Sleep Number smart beds (mattress systems), which typically represent the largest portion of product sales. Additional revenue is generated from complementary products sold alongside beds, including adjustable bases/furniture components, pillows, sheets and other bedding, and accessories. The company sells through its owned store network and e-commerce/phone channels, capturing retail margin rather than wholesaling broadly to third-party retailers. Sleep Number also generates revenue from services and other related items such as delivery and setup/installation fees where applicable, and from extended service plans/warranties if offered to customers. Financing programs offered to consumers (often facilitated through third-party credit providers) can support conversion and ticket size; if any income is earned from these arrangements beyond product sales (e.g., program-related fees), specific details are null. Significant factors influencing earnings include unit volume and average selling price of smart beds, attachment rates of accessories and bases, promotional cadence/discounting, and the costs of operating company-owned retail and fulfillment/manufacturing operations.

Sleep Number Earnings Call Summary

Earnings Call Date:Mar 12, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Positive
The call presented meaningful evidence of a successful operational turnaround: product launch traction (Comfort mode selling well), substantial cost reductions ($185M executed plus $50M identified), improved adjusted EBITDA (beat guidance), and strengthening brand metrics. However, the company continues to face significant top-line pressure (FY sales down 16%, Q4 and Q1 softness), a Q4 inventory obsolescence charge, short-term margin headwinds from clearance activity, and ongoing liquidity and capital-structure work. Overall, the tone is cautiously optimistic — strong early wins and clear operational progress offset by material near-term revenue and liquidity challenges.
Q4-2025 Updates
Positive Updates
Adjusted EBITDA Beat
Full-year adjusted EBITDA of $78 million exceeded prior guidance of $70 million, with pro forma adjusted EBITDA margin approximately 9%, a ~200 basis point improvement versus the prior year.
Product Launch Early Outperformance
Comfort mode mattress (10-inch) launched in January is selling 3.5x the company's plan through end of February and nearly 2x the combined sales of the three C Series beds it replaces; comfort mode shows a ~10 percentage point gross margin improvement versus the replaced C Series SKUs.
Significant Cost Reductions
Executed approximately $185 million of annualized cost savings in 2025 and identified an incremental $50 million of annualized fixed cost reductions to be executed in 2026, supporting margin recovery and lower cash burn.
Full-Year Sales In Line with Guidance
Full-year net sales of $1.41 billion were in line with company guidance despite reduced marketing spend and lower traffic during the year.
Marketing and Brand Momentum
Marketing funnel metrics improved through 2025; brand consideration among premium shoppers grew 10% and reached the highest consideration in the premium category, with highest levels in six years on key drivers (value, quality, comfort, individualized comfort).
Lower-than-Expected Cash Use and Liquidity Compliance
Use of cash for 2025 was $18 million versus a $50 million guidance (better than expected). Total liquidity (cash + revolver) was $58 million at year-end, above the amended $30 million covenant floor, and the company remained in compliance with credit covenants.
Operational Execution Speed
Completed a large-scale product reset in ~10 months (work typically taking >2 years), enabling a simplified lineup (from 12 to 7 mattresses) and a faster go-to-market for new SKUs available starting March 23 with most floors set by mid-April.
Forward Improvement Outlook
Company expects significant revenue improvement in Q2, double-digit sales growth in the second half of 2026, adjusted EBITDA growth in the high teens to mid-20s percent year-over-year, and positive free cash flow for 2026 (no formal guidance provided).
Negative Updates
Top-Line Pressure and YoY Declines
Q4 net sales were $347 million, down 8% versus the prior year; full-year net sales declined 16% year-over-year (prior year benefited from a 53rd week, ~660 basis points impact).
Q4 Gross Margin Impacted by Inventory Charge
Q4 gross profit margin declined to 55.6%, a 430 basis point drop year-over-year, primarily due to a $9.6 million nonrecurring inventory obsolescence charge, unit deleverage and higher tariffs; adjusted Q4 gross margin excluding the charge was 58.4%.
Liquidity and Capital Structure Pressure
Management flagged ongoing pressure on liquidity and covenants driven by industry softness, inventory clearance, and conservative marketing timing; Guggenheim Securities has been engaged to evaluate refinancing and other options to improve capital structure.
Store Disruptions and Footprint Reduction
236 stores were closed at least one day in January due to severe weather (negatively impacting early-year sales), and store count decreased by 40 during the year to finish with 600 stores, reflecting contraction and rollout/logistics work for new products.
Inventory Clearance and Short-Term Margin Headwinds
Company is executing clearance of legacy SKUs as part of the product reset, creating expected Q1 margin pressure and increased markdown activity; management acknowledged inventory 'hangover' into March and some unexpected clearance impact.
Free Cash Flow and YoY Cash Performance
Full-year free cash flow was a use of $18 million—about $30 million better than plan but $21 million unfavorable versus prior year—driven by top-line pressure and nonrecurring cash restructuring costs.
Near-Term Revenue Guidance Not Provided
Given the magnitude of the reset and uncertainty from early-year softness, management did not provide formal 2026 guidance, creating short-term visibility uncertainty despite directional expectations for improvement.
Company Guidance
Sleep Number did not provide formal 2026 guidance but gave directional targets: Q1 net sales are expected to decline in the high‑teens, with a significant sequential improvement in Q2 and double‑digit sales growth in the second half; full‑year adjusted EBITDA is expected to increase in the high‑teens to mid‑20s percent versus 2025’s $78M (2025 pro‑forma adjusted EBITDA margin ≈9%), and the company expects positive free cash flow for 2026; marketing spend is planned roughly flat year‑over‑year but rephased (Q1 down, Q2 up, back half ~flat), capex was $14M in 2025, full‑year 2025 net sales were $1.41B (Q4 $347M, -8% YoY), full‑year 2025 gross margin was 59% (58.4% adjusted in Q4 excluding a $9.6M inventory charge), total liquidity at year‑end was $58M (vs. amended covenant floor $30M), the company cut ~$185M of annualized costs in 2025 with an identified incremental $50M of annualized fixed cost savings to execute in 2026, and management has engaged Guggenheim to evaluate refinancing and other options to improve the capital structure.

Sleep Number Financial Statement Overview

Summary
Financial fundamentals are highly strained: profitability has shifted from 2020–2021 gains to sustained losses (TTM net margin about -5.4%), cash flow has reverted to negative in TTM after only a modest 2024 rebound, and the balance sheet is stressed with persistent negative equity and very high debt relative to assets—limiting flexibility and increasing financial risk.
Income Statement
22
Negative
Profitability has deteriorated materially. After solid earnings in 2020–2021 (net margins ~7%), results flipped to losses from 2022 through 2024 (net margin -1.2% in 2024) and worsened in TTM (Trailing-Twelve-Months) with negative EBIT and a net margin of about -5.4%. Gross margin has held relatively steady near ~57%–60%, but operating leverage has weakened. Revenue trends are also unfavorable: modest declines in 2022–2024 followed by an extreme revenue contraction shown in TTM (Trailing-Twelve-Months), signaling significant demand disruption and/or reporting volatility.
Balance Sheet
14
Very Negative
The balance sheet is the key pressure point: stockholders’ equity is negative across all periods (and more negative in TTM versus 2024), which reduces financial flexibility and elevates risk. Total debt remains very large relative to the asset base (e.g., debt of ~$936M vs. assets of ~$861M in 2024), and the negative equity makes leverage ratios difficult to interpret but directionally underscores high leverage. Overall, the capital structure looks stressed and leaves limited cushion if operating performance remains weak.
Cash Flow
24
Negative
Cash generation has become inconsistent. Operating cash flow was strong in 2020–2021 but turned negative in 2023 and again in TTM (Trailing-Twelve-Months), while free cash flow was negative in most recent periods (notably 2022, 2023, and deeply negative in TTM). 2024 showed a modest rebound to positive free cash flow, but the reversion to negative operating and free cash flow in TTM suggests the improvement did not hold. This weakens the company’s ability to self-fund operations and service debt without external support.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.41B1.68B1.89B2.11B2.18B
Gross Profit832.95M1.00B1.09B1.20B1.32B
EBITDA57.30M89.22M95.34M135.28M253.93M
Net Income-131.96M-20.33M-15.29M36.61M153.75M
Balance Sheet
Total Assets680.06M860.81M950.88M953.94M919.54M
Cash, Cash Equivalents and Short-Term Investments1.69M1.95M2.54M1.79M2.39M
Total Debt354.30M936.11M972.65M896.01M791.05M
Total Liabilities1.26B1.31B1.39B1.39B1.34B
Stockholders Equity-578.48M-451.59M-441.93M-438.18M-424.95M
Cash Flow
Free Cash Flow-17.69M3.64M-66.08M-33.32M233.11M
Operating Cash Flow-3.28M27.14M-9.03M36.14M300.01M
Investing Cash Flow-17.69M-26.29M-58.35M-70.61M-66.64M
Financing Cash Flow20.71M-1.44M68.13M33.87M-235.22M

Sleep Number Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.31
Price Trends
50DMA
8.52
Negative
100DMA
7.41
Negative
200DMA
7.86
Negative
Market Momentum
MACD
-1.56
Positive
RSI
20.64
Positive
STOCH
10.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNBR, the sentiment is Negative. The current price of 3.31 is below the 20-day moving average (MA) of 5.99, below the 50-day MA of 8.52, and below the 200-day MA of 7.86, indicating a bearish trend. The MACD of -1.56 indicates Positive momentum. The RSI at 20.64 is Positive, neither overbought nor oversold. The STOCH value of 10.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNBR.

Sleep Number Risk Analysis

Sleep Number disclosed 1 risk factors in its most recent earnings report. Sleep Number reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sleep Number Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$568.47M12.459.20%7.86%-4.26%
65
Neutral
$1.35B18.088.12%2.39%1.78%-25.36%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
59
Neutral
$1.23B11.21-1.98%4.16%4.34%-141.36%
57
Neutral
$1.39B6.4726.15%1.84%-6.03%
48
Neutral
$75.68M-2.12-9999.00%-9.47%48.11%
41
Neutral
$75.68M0.6716.35%-16.95%-88.00%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNBR
Sleep Number
3.31
-3.49
-51.32%
ETD
Ethan Allen
22.34
-3.30
-12.88%
MLKN
MillerKnoll
18.08
-0.42
-2.28%
LZB
La-Z-Boy Incorporated
33.07
-4.71
-12.48%
LEG
Leggett & Platt
10.21
2.11
26.06%
PRPL
Purple Innovation
0.70
-0.11
-13.83%

Sleep Number Corporate Events

Business Operations and StrategyFinancial Disclosures
Sleep Number details turnaround progress and transformation plans
Positive
Mar 12, 2026

On March 12, 2026, Sleep Number posted a detailed investor presentation outlining the progress of its ongoing turnaround and financial and operational transformation. The company highlighted 2025 net sales of $1.41 billion in line with guidance, adjusted EBITDA of $78 million above outlook, more than $185 million in annualized cost reductions with another $50 million being executed, and a reshaped leadership team focused on restoring profitable growth.

Management said 2025 was a pivotal year, citing the successful launch of its ComfortMode mattress, which exceeded sales expectations by 3.5 times, and the planned March 23 reset of its entire product line to emphasize comfort, durability, adjustability and value at more approachable premium price points. Sleep Number is also rebuilding its marketing engine, pursuing new physical and digital distribution, and working to address liquidity and capital structure, including retaining Guggenheim Securities to evaluate options to improve its balance sheet and financial flexibility as it targets topline growth in the second half of the year and a return to free cash flow generation in 2026.

The most recent analyst rating on (SNBR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.

Executive/Board Changes
Sleep Number Names Kelly Baker Principal Accounting Officer
Neutral
Mar 12, 2026

On March 10, 2026, Sleep Number’s board appointed Kelly F. Baker as the company’s Controller and Principal Accounting Officer, effective March 11, 2026, formalizing a role she had held on an interim basis since July 21, 2025. The move solidifies the company’s finance leadership structure, drawing on Baker’s public accounting background and finance roles at Miromatrix Medical, Donaldson Company, The Tile Shop, and Virtual Radiologic, and comes with no special arrangements or related-party transactions disclosed in connection with her selection.

The most recent analyst rating on (SNBR) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Sleep Number launches strategic partnership with Travis Kelce
Positive
Jan 28, 2026

On January 28, 2026, Sleep Number announced a three-year strategic partnership and investment deal with three-time Super Bowl champion Travis Kelce, who has used the company’s products since 2019. Under the agreement, Kelce and his company TMK Enterprises LLC will collaborate on national advertising and digital content to promote the performance and wellness benefits of Sleep Number beds, while Kelce receives cash and restricted stock units that vest over three years and commits to buying additional shares on the open market, making him one of the company’s largest shareholders with under 5% ownership. The deal deepens Sleep Number’s long-standing relationship with the NFL—where 83% of players have Sleep Number beds—and is a key element of the company’s broader effort to overhaul its marketing strategy, sharpen brand visibility and attract younger consumers by leveraging Kelce’s high profile and alignment with sleep-focused performance.

The most recent analyst rating on (SNBR) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 13, 2026